Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ALXN1910 · 1 trial · 1 indication
The safety and tolerability of ALXN1910 was assessed.
| Arm | Type | Description |
|---|---|---|
| Cohort 1 | EXPERIMENTAL | Participants will receive a single dose of 5 mg of ALXN1910 IV or Placebo IV. |
| Cohort 2 | EXPERIMENTAL | Participants will receive a single dose of 15 mg of ALXN1910 SC or Placebo SC. |
| Cohort 3 | EXPERIMENTAL | Participant will receive a single dose of 15 mg of ALXN1910 IV or Placebo IV. |
| Cohort 4 | EXPERIMENTAL | Japanese participants will receive a single dose of 15 mg of ALXN1910 SC or Placebo SC. |
| Cohort 5 | EXPERIMENTAL | Participants will receive a single dose of 45 mg of ALXN1910 SC or Placebo SC. |
| Cohort 6 | EXPERIMENTAL | Participants will receive a single dose of 135 mg of ALXN1910 SC or Placebo SC. |
| Name | Type | Description |
|---|---|---|
| ALXN1910 | DRUG | Participants will receive a single dose of ALXN1910 IV or ALXN1910 SC according to their assigned cohort. |
| Placebo | DRUG | Participants will receive Placebo IV or Placebo SC according to their assigned cohort. |
Inclusion Criteria: * Healthy participants * Participants of Japanese descent are defined as: First generation (born to 2 Japanese parents and 4 Japanese grandparents). * Participants of Japanese descent must be between 20 and 55 years of age. Exclusion Criteria: * Current or recurrent disease * ...
ALXN1910 is an investigational small molecule being developed by AstraZeneca PLC (AZN). It is currently in Phase 1 clinical development. The drug has been studied in healthy participants, and its therapeutic area is classified as Other.
ALXN1910 is being studied for use in healthy participants. It is an investigational small molecule in Phase 1 clinical development. The drug is not approved for any indication and is still in early-stage clinical trials.
ALXN1910 is being developed by AstraZeneca PLC, which trades under the ticker AZN. The company is conducting clinical trials to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of this investigational small molecule.
ALXN1910 is in Phase 1 clinical development. It is an investigational drug, meaning it is not yet approved by regulatory authorities. The drug has completed one Phase 1 trial in healthy participants.
ALXN1910 has one completed clinical trial, NCT05307978, which was a Phase 1 study in healthy participants. The trial, conducted in the United Kingdom, enrolled 48 participants and evaluated the safety, tolerability, pharmacokinetics, and pharmacodynamics of the drug.
ALXN1910 is the primary name for this investigational drug. No alternative names have been reported for this asset. It is a small molecule being developed by AstraZeneca PLC and is currently in Phase 1 clinical trials.